Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias
- PMID: 7718886
Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias
Abstract
Chronic myelogenous leukemia is characterized by the Philadelphia chromosome, which at the molecular level results from the fusion of the bcr gene on chromosome 22 and the abl gene on chromosome 9. The bcr-abl fusion gene encodes a novel tyrosine kinase with transforming activity. In this study, we have synthesized a multi-unti ribozyme that targets bcr-abl mRNA. In vitro ribozyme cleavage reactions show increased cleavage efficiency of this multi-unit ribozyme compared with single or double ribozymes. The multiunit ribozyme was then transfected into murine myeloblasts transformed with the bcr-abl gene (32D cells). Ribozyme transfection was accomplished either by liposomes or using follic acid-polylysine as a carrier. Multi-unit ribozyme transfection reduced the level of bcr-abl mRNA 3 logs when transfected via folate receptor-mediated uptake into transformed 32D cells. These results suggest that a multi-unit ribozyme could be an effective therapeutic agent for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.
Similar articles
-
Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.Leuk Lymphoma. 1996 Aug;22(5-6):365-73. doi: 10.3109/10428199609054774. Leuk Lymphoma. 1996. PMID: 8882949 Review.
-
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.Cancer Gene Ther. 2002 Jan;9(1):71-86. doi: 10.1038/sj.cgt.7700410. Cancer Gene Ther. 2002. PMID: 11916246
-
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.Blood. 1993 Jul 15;82(2):600-5. Blood. 1993. PMID: 8329715
-
Ribozyme mediated therapy for chronic myelogenous leukemia.Prog Clin Biol Res. 1994;389:175-82. Prog Clin Biol Res. 1994. PMID: 7700900 No abstract available.
-
Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.Leuk Lymphoma. 1993;11 Suppl 1:139-43. doi: 10.3109/10428199309047877. Leuk Lymphoma. 1993. PMID: 8251887 Review.
Cited by
-
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.Nucleic Acids Res. 1997 Aug 1;25(15):3074-81. doi: 10.1093/nar/25.15.3074. Nucleic Acids Res. 1997. PMID: 9224607 Free PMC article.
-
Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.Cytotechnology. 1998 Sep;27(1-3):113-36. doi: 10.1023/A:1008052401952. Cytotechnology. 1998. PMID: 19002787 Free PMC article.
-
Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.Br J Cancer. 1999 Mar;79(9-10):1325-31. doi: 10.1038/sj.bjc.6690214. Br J Cancer. 1999. PMID: 10188872 Free PMC article.
-
A Bibliometric analysis of folate receptor research.BMC Cancer. 2020 Nov 16;20(1):1109. doi: 10.1186/s12885-020-07607-5. BMC Cancer. 2020. PMID: 33198687 Free PMC article.
-
Antisense approaches to the gene therapy of cancer--'Recnac'.Cancer Metastasis Rev. 1996 Sep;15(3):287-99. doi: 10.1007/BF00046343. Cancer Metastasis Rev. 1996. PMID: 9034592 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous